Table 1.

Patients characteristics

Age, yr	Sex	Race	Primary tumor location	Prior liver metastasis resection	Sites of metastases when on treatment	Prior PD‐1/PD‐L1 inhibitor	Duration and response on prior PD‐1/PD‐L1 inhibitor, mo	ECOG PS	Regimen	TMB (mutations per Mb)	No. of Cycles	Response
55	M	White	Left	Yes	Lung	Yes	PD (2)	0	Rego + nivo	3	2	PD
75	M	White	Right	Yes	Lung	No		0	Rego + nivo	3	2	PD
53	M	White	Left	No	Lung, peritoneum	Yes	SD (16)	1	Rego + nivo	2	8	SD
67	M	Asian	Left	No	Lung	Yes	SD (8)	1	Rego + pem	4	9	SD
52	M	White	Right	No	Liver, lymph node	No		1	Rego + nivo	7	2	PD
73	M	Asian	Right	Yes	Lung	No		1	Rego + nivo	11	2	PD
65	M	White	Left	Yes	Liver, peritoneal, spleen, RPLN	No		1	Rego + nivo	4	2	PD
65	M	White	Right	No	Liver, lung, lymph node	Yes	PD (1)	1	Rego + nivo	NA	2	PD
60	M	NA	Left	No	Lung, RPLN	No		1	Rego + nivo	5	7	SD
57	M	NA	Left	Yes	Lung	No		0	Rego + nivo	7	4	SD
75	M	Asian	Left	Yes	Liver, lung, bone	No		1	Rego + nivo	6	2	PD
43	M	Asian	Left	Yes	Liver, lung, peritoneum, lymph node	Yes	PD (1)	1	Rego + nivo	NA	4	PD
48	M	White	Left	Yes	Liver, lung	No		1	Rego + nivo	6	3	PD
67	F	White	Left	Yes	Lung, RPLN, hilar adenopathy, brain	No		0	Rego + nivo	NA	2	PD
54	M	Asian	Left	Yes	Liver, lung, RPLN	No		1	Rego + nivo	2	2	PD
60	M	White	Right	Yes	Lung	Yes	SD (5)	1	Rego + nivo	2	1	PD
47	M	White	Left	No	Pelvic	No		0	Rego + nivo	4	4	SD
79	F	White	Right	No	Liver, lymph nodes	No		1	Rego + nivo	6	1	PD

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; F, female; M, male; NA, not available; Nivo, nivolumab; PD, progressive disease; PD‐1, programmed cell death protein 1; PD‐L1, programmed death‐ligand 1; Pem, pembrolizumab; Rego, regorafenib; RPLN, retroperitoneal lymph node; SD, stable disease; TMB, tumor mutation burden.